Tibet Duo Rui Pharmaceutical Co.Ltd(301075)
Special report on the annual storage and use of raised funds
According to the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies (SZS [2022] No. 14) and relevant format guidelines issued by Shenzhen Stock Exchange, the deposit and use of the company’s raised funds in 2021 are specially explained as follows.
1、 Basic information of raised funds
（1） Actual amount of raised funds and time of fund arrival
According to the reply on Approving the registration of Tibet Duo Rui Pharmaceutical Co.Ltd(301075) initial public offering of shares (zjxk [2021] No. 2760) issued by China Securities Regulatory Commission, the company has Citic Securities Company Limited(600030) issued 20 million RMB ordinary shares (A shares) to the public by the lead underwriter through fixed price issuance, with an issue price of 27.27 yuan per share, raising a total of 545.4 million yuan, The raised capital after deducting the underwriting fee of 37.596 million yuan was 507804 million yuan, which was remitted to the raised capital supervision account of the company by the lead underwriter Citic Securities Company Limited(600030) on September 23, 2021. In addition, after deducting 257543 million yuan of additional external expenses directly related to the issuance of equity securities, such as online issuance fee, prospectus printing fee, recommendation fee, reporting accountant fee and lawyer fee, the net amount of funds raised by the company this time is 4820497 million yuan. The availability of the above-mentioned raised funds has been verified by Tianjian Certified Public Accountants (special general partnership) and issued a capital verification report (Tianjian Yan [2021] No. 535).
（2） Use and balance of raised funds
Monetary unit: RMB 10000
Item No. amount
Net amount of raised funds a 4820497
Project input B1
Accumulated amount as of the beginning of the period
Net interest income B2
Project investment C1 301753 current amount
Net interest income C2 71.45
Accumulated amount by the end of the period: project investment D1 = B1 + C1 301753
Item No. amount
Net interest income D2 = B2 + C2 71.45
Balance of raised funds to be raised e = a-d1 + D24525889
Actual balance of raised funds f 4572878
Including: balance of special account for deposited raised funds F11815557
Undue bank financial product F22757321
Difference g = E-F -469.89 [note]
[note] it means that the company replaces the self raised funds of RMB 4.6951 million and the outstanding issuance expenses of RMB 3800 with the raised funds. As of December 31, 2021, the replacement and payment have not been completed. As of the date of issuing the report, the company has completed the replacement and payment.
2、 Deposit and management of raised funds
（1） Management of raised funds
In order to standardize the management and use of raised funds, improve the efficiency and efficiency of fund use, and protect the rights and interests of investors, In accordance with the company law of the people’s Republic of China, the securities law of the people’s Republic of China, the Listing Rules of GEM stocks of Shenzhen Stock Exchange (revised in December 2020) (SZS [2020] No. 1292) and the self regulatory guidelines for listed companies of Shenzhen Stock Exchange No. 2 – standardized operation of GEM listed companies (SZS [2022] No. 14) and other relevant laws, regulations and normative documents, In combination with the actual situation of the company, the management system of Tibet Duo Rui Pharmaceutical Co.Ltd(301075) raised funds (hereinafter referred to as the management system) is formulated. According to the management system, the company implements a special account for the raised funds, establishes a special account for the raised funds in the bank, and together with the sponsor Citic Securities Company Limited(600030) signed the tripartite supervision agreement for the raised funds with Wuhan Branch of Hengfeng Bank Co., Ltd., Industrial Bank Co.Ltd(601166) Wuhan branch, China Citic Bank Corporation Limited(601998) Lhasa branch and China Citic Bank Corporation Limited(601998) Wuhan Branch on October 20, 2021, On October 20, 2021, the four party supervision agreement on raised funds was signed with the subsidiary Hubei Duorui Pharmaceutical Co., Ltd. and China Minsheng Banking Corp.Ltd(600016) Lhasa branch, clarifying the rights and obligations of all parties. There is no significant difference between the three-party supervision agreement, the four-party supervision agreement and the model three-party supervision agreement of Shenzhen Stock Exchange. The company has strictly complied with the raised funds.
（2） Storage of raised funds in special account
As of December 31, 2021, the company has five special accounts for raised funds, one time deposit account, two call deposit accounts and five large deposit certificate accounts. The deposits of raised funds are as follows:
Monetary unit: RMB
Remarks bank account balance of raised funds
Remarks on the balance of raised funds in the account number of the deposit bank
66486666964116.52 current account
7204476489273211630 7-day call deposit
720448042 Shanghai Pudong Development Bank Co.Ltd(600000) 0000 1-year time deposit
China China Minsheng Banking Corp.Ltd(600016) Lhasa branch 7085737631000000000 certificate of deposit
Bank business department 7085746271000000000 certificate of deposit
7082608051000000000 certificate of deposit
7082590671000000000 certificate of deposit
7082609011000000000 certificate of deposit
Current account of Hengfeng Bank Co., Ltd. 80271001012280626077904174
Division Wuhan Branch Business Department 4205020110010 China Vanke Co.Ltd(000002) 73000000000 seven day call deposit
Industrial Bank Co.Ltd(601166) Co., Ltd. 41 Wenfeng Great World Chain Development Corporation(601010) 22916184491319317 current account
Wuhan Branch Sales Department
China Citic Bank Corporation Limited(601998) Co., Ltd. 8116201013 Eve Energy Co.Ltd(300014) 3423337723600 current account
Lhasa Branch Sales Department
China Citic Bank Corporation Limited(601998) Co., Ltd. 8111501011 Guangzhou Haoyang Electronic Co.Ltd(300833) 19110242211754 current account
Wuhan Donghu sub branch
Total 45728782127
3、 Actual use of raised funds this year
（1） Comparison table of use of raised funds
1. See the annex of this report for the comparison table of the use of raised funds.
2. Use of over raised funds in the current period
Through the resolution adopted at the 9th meeting of the first board of directors on December 24, 2021, it is agreed that the company will use the over raised capital of 26.3 million yuan to permanently supplement the working capital. This matter has been deliberated and approved by the first extraordinary general meeting of shareholders in 2022. 3. Other use of raised funds
According to the resolution of the company’s second extraordinary general meeting of shareholders in 2021 on November 8, 2021, the company will invest some idle raised funds of no more than 45 million yuan in financial products with a term of no more than 12 months (including but not limited to principal guaranteed financial products, time deposits, structured deposits, large certificates of deposit, call deposits, agreement deposits, etc.).
(1) On November 25, 2021, the company signed an agreement with Citic Securities Company Limited(600030) to purchase principal guaranteed financial products by using some idle raised funds totaling 100 million yuan. The product name is ” Citic Securities Company Limited(600030) profit saving and profit increasing series 1422 income voucher”, the product yield is 2.00% – 3.60% per year, and the value date of the product is November 26, 2021,
The maturity date is February 24, 2022. The company has redeemed in advance on December 29, 2021.
(2) On December 2, 2021, the subsidiary Hubei Duorui Pharmaceutical Co., Ltd. signed an agreement with the business department of China Minsheng Banking Corp.Ltd(600016) Lhasa branch to purchase a 7-day call deposit with a total of 142.54 million yuan of idle raised funds. The product name is “smart call deposit”, the product yield is 2.10%, the value date of the product is December 2, 2021, and the maturity date is automatically renewed from the withdrawal date (i.e. “t + 7”). The financial product has been recovered in December 2021.
(3) On December 2, 2021, the company signed an agreement with the business department of China Minsheng Banking Corp.Ltd(600016) Lhasa branch to purchase fixed-term deposits with a total of 60 million yuan of idle raised funds. The product name is “issuing fixed-term deposits to corporate customers”. The product yield is 2.25%, the value date of the product is December 2, 2021, and the maturity date is December 2, 2022.
(4) On December 16, 2021, the company signed an agreement with Wuhan Branch of Hengfeng Bank Co., Ltd. to purchase fixed-term deposits with a total of 73 million yuan of idle raised funds. The product name is “unit call deposit”. The product yield is calculated according to the seven-day notice deposit published on the withdrawal date. The value date of the product is December 16, 2021, and the maturity date is the non agreed deposit period. The bank shall be notified in advance when withdrawing.
(5) On December 20, 2021, the subsidiary Hubei Duorui Pharmaceutical Co., Ltd. signed an agreement with the business department of China Minsheng Banking Corp.Ltd(600016) Lhasa branch to purchase time deposits with a total of 20 million yuan of idle raised funds. The product name is “exclusive issue 19 of 2021 corporate transferable certificate of deposit (three-year term is transferred by half a year)”, the product yield is 3.30% per year, and the value and interest date of the product is December 20, 2021, The maturity date is June 20, 2022.
(6) On December 20, 2021, the subsidiary Hubei Duorui Pharmaceutical Co., Ltd. signed an agreement with the business department of China Minsheng Banking Corp.Ltd(600016) Lhasa branch to purchase fixed-term deposits with a total of 30 million yuan of idle raised funds. The product name is “phase 239 exclusive for corporate transferable certificates of deposit in 2020 (2 years of quarterly interest payment)”, and the product yield is 2.90% per year
